美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

GSK plc ADRhedged

69.80

+2.834.23%

盤後：69.800.00000.00%16:10 EDT

成交量：858

成交額：5.98萬

市值：69.81萬

市盈率：- -

高：70.05

開：69.80

低：69.34

收：66.97

52周最高：85.03

52周最低：55.75

股本：1.00萬

流通股本：1.00萬

量比：4.75

換手率：8.58%

股息：2.08

股息率：2.97%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

118款生物藥專利懸崖將至，中國藥企業迎戰MNC最大專利懸崖

乙肝新藥中國數據出爐，但實現患者的「治癒夢」仍有門檻

每日经济新闻

功能性治癒率最高61%！乙肝新藥中國數據出爐但7500萬患者的「治癒夢」仍有門檻

每日经济新闻

總額可達12.95億美元！和黃全球首創偶聯藥物出海

和黃醫藥午後飆升逾16%，與葛蘭素史克達成最高12.95億美元腫瘤藥授權合作

老虎资讯综合

藥聞 | 英硅智能上市後首份半年報扭虧創新藥研發加速擁抱AI

聯環藥業上半年扭虧為盈集採續採與創新藥研發協同推進

能夠治癒乙肝的新藥來了？專家：距離攻克乙肝仍有差距，但臨床多了一件新武器

每日经济新闻

葛蘭素史克(GSK)擬發行至少20億歐元債券，以償還併購融資貸款。

博濟醫藥2026年半年報：創新藥研發需求復甦，在手訂單充足，經營現金流明顯下滑

GSK：NUCALA獲加拿大藥品管理局積極報銷推薦，用於成人慢性阻塞性肺疾病治療。

中外製藥與葛蘭素史克簽署抗登革熱病毒抗體「AID351」獨家許可協議

中外製藥與葛蘭素史克達成協議，共同推進登革熱抗體藥物開發

中國銀河證券：實驗動物為創新藥研發剛需小鼠+猴雙主線高景氣

葛蘭素史克：董事會批准根據公司淨資產，按資產市場價值分配公司合併後股本。

百花醫藥股價嚴重異常波動：主營小分子化學仿製藥CRO業務不涉及創新藥研發

百花醫藥(600721.SH)：不涉及創新藥研發

百花醫藥(600721.SH)：不涉及創新藥研發

東方證券：AI重構創新藥研發底座國內相關產業鏈公司亦有望受益

數據簡報-全球製藥企業斥資數十億以擴大在美國的市場份額

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/hant/stock/GSKH/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"GSKH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GSKH\",,,,,undefined,":{"symbol":"GSKH","market":"US","secType":"STK","nameCN":"GSK plc ADRhedged","latestPrice":69.8025,"timestamp":1789416000000,"preClose":66.9705,"halted":0,"volume":858,"hourTrading":{"tag":"盘后","latestPrice":69.8025,"preClose":69.8025,"latestTime":"16:10 EDT","volume":6,"amount":418.81499999999994,"timestamp":1789416603787,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.042287275740811155,"floatShares":10001,"shares":10001,"eps":0,"marketStatus":"盤後交易","change":2.832,"latestTime":"09-14 18:32:00 EDT","open":69.8,"high":70.05,"low":69.34,"amount":59772,"amplitude":0.010602,"askPrice":104.71,"askSize":200,"bidPrice":34.91,"bidSize":200,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1789430400000},"marketStatusCode":4,"adr":0,"exchange":"ARCA","adjPreClose":66.9705,"nav":66.980718,"aum":669874.160718,"dividendRate":0.029742,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":69.8025,"preClose":69.8025,"latestTime":"16:10 EDT","volume":6,"amount":418.81499999999994,"timestamp":1789416603787,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":4.745573,"impliedVol":0.1896,"impliedVolPercentile":0.4649},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GSKH\",,,,,undefined,":{"symbol":"GSKH","floatShares":10001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":4.745573,"shares":10001,"dividePrice":2.0761,"high":70.05,"amplitude":0.010602,"preClose":66.9705,"low":69.34,"week52Low":55.7526,"pbRate":"--","week52High":85.03,"institutionHeld":0,"latestPrice":69.8025,"eps":0,"divideRate":0.029742,"volume":858,"delay":0,"ttmEps":0,"open":69.8,"prevYearClose":68.2031,"prevWeekClose":66.9705,"prevMonthClose":69.8569,"prevQuarterClose":73.8574,"fiveDayClose":69.5112,"twentyDayClose":68.9018,"sixtyDayClose":73.2027},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GSKH\",params:#limit:5,,,undefined,":[{"date":"2026-06-16","symbol":"GSKH","amount":0.92785,"announcedDate":"2026-06-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-16","defaultRemindTime":1781616600000,"name":"GSK plc ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-23","payableDate":"2026-06-16","currency":"USD","dateTimestamp":1781582400000,"payDate":"2026-06-23"},{"date":"2026-03-16","symbol":"GSKH","amount":0.36332,"announcedDate":"2026-03-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-16","defaultRemindTime":1773667800000,"name":"GSK plc ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-23","payableDate":"2026-03-16","currency":"USD","dateTimestamp":1773633600000,"payDate":"2026-03-23"},{"date":"2025-12-16","symbol":"GSKH","amount":0.78682,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"GSK plc ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-24","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-24"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GSKH\",market:\"US\",,,undefined,":[{"executeDate":"2025-12-16","recordDate":"2025-12-16","paymentDate":"2025-12-24","value":0.78682,"currency":"USD"},{"executeDate":"2026-03-16","recordDate":"2026-03-16","paymentDate":"2026-03-23","value":0.36332,"currency":"USD"},{"executeDate":"2026-06-16","recordDate":"2026-06-16","paymentDate":"2026-06-23","value":0.92785,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GSKH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GSKH\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666563124","title":"118款生物藥專利懸崖將至，中國藥企業迎戰MNC最大專利懸崖","url":"https://stock-news.laohu8.com/highlight/detail?id=2666563124","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666563124?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 15:26","pubTimestamp":1789025185,"startTime":"0","endTime":"0","summary":"BCG合伙人杜菁博士指出，未来几年全球MNC将迎来史上最大专利悬崖，有118种生物制剂将会失去相应的专利保护，涉及2340亿美元市场。然而，目前这118款即将到期分子中，只有极少数在火热开发，大量缺口有待生物类似药填补。目前来说，创新药出海还没办法完成这个闭环，但生物类似药作为先头部队做出海试验，企业风险和获益会更高。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1789025064363150858","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["RSPH","159839","PJP","BBP","APXH","BME","MEDI","TMED","PBPH","GSKH","IHE","BBH","IYH","PPH","TRUH","FXH","JDOC","FHLC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665937331","title":"乙肝新藥中國數據出爐，但實現患者的「治癒夢」仍有門檻","url":"https://stock-news.laohu8.com/highlight/detail?id=2665937331","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665937331?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 20:51","pubTimestamp":1788871868,"startTime":"0","endTime":"0","summary":"中国慢性乙型肝炎（以下简称慢乙肝）患者的“治愈”故事，正在萌芽。日前，在新加坡召开的亚洲肝病学峰会暨乙肝病毒治愈科学会议上，反义寡核苷酸（ASO）药物Bepirovirsen全球Ⅲ期研究（BWell研究）的中国人群数据完成了全球首秀：中国慢乙肝患者功能性治愈率最高可达61%，疗效与安全性趋势与全球数据一致。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609083868286383.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609083868286383.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4007","BK4585","LU1829250122.USD","BK4532","GSK","GSKH","GSK.UK","BK4561","ASO","BK4588","BK4200"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665535012","title":"功能性治癒率最高61%！乙肝新藥中國數據出爐 但7500萬患者的「治癒夢」仍有門檻","url":"https://stock-news.laohu8.com/highlight/detail?id=2665535012","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665535012?lang=zh_tw&edition=fundamental","pubTime":"2026-09-05 12:14","pubTimestamp":1788581677,"startTime":"0","endTime":"0","summary":"【功能性治愈率最高61%！乙肝新药中国数据出炉 但7500万患者的“治愈梦”仍有门槛】8月31日—9月5日，在新加坡召开的亚洲肝病学峰会（AHS）暨HBV（乙型肝炎病毒）治愈科学会议上，反义寡核苷酸（ASO）药物Bepirovirsen全球Ⅲ期研究（B-Well研究）的中国人群数据完成了全球首秀：中国慢乙肝患者功能性治愈率最高可达61%，疗效与安全性趋势与全球数据一致。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609053865995314.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609053865995314.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["XME","CHB","LU1829250122.USD","BK4007","BK4561","BK4599","CDE","ASO","BK4532","BK4139","BK4585","SIL","LU1223083913.SGD","GSK.UK","ALT","LU1223082196.USD","SGDM","GSKH","BK4588","LU1223082519.USD","LU1878469433.USD","GDXJ","GSK","BK4200","BK4017"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664960827","title":"總額可達12.95億美元！和黃全球首創偶聯藥物出海","url":"https://stock-news.laohu8.com/highlight/detail?id=2664960827","media":"时代周报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664960827?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 16:03","pubTimestamp":1788422625,"startTime":"0","endTime":"0","summary":"9月3日，和黄医药（00013.HK）宣布旗下子公司和记黄埔与葛兰素史克（GSK）附属公司达成独家开发及许可协议，授予后者除中国大陆、香港、澳门和台湾以外的全球范围内开发和商业化HMPL-A830的权利。临床开发将首先聚焦于结直肠癌、胰腺癌和肺癌适应症。协议包括1.1亿美元的首付款以及潜在的开发、注册和商业化里程碑付款，总额可达12.95亿美元，外加基于净销售额的特许权使用费。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609033864044420.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609033864044420.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","BK4532","GSK.UK","GSKH","LU1829250122.USD","BK1588","BK4007","BK4585","BK4588","BK1587","00013","GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124565155","title":"和黃醫藥午後飆升逾16%，與葛蘭素史克達成最高12.95億美元腫瘤藥授權合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1124565155","media":"老虎资讯综合","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124565155?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 15:56","pubTimestamp":1788422188,"startTime":"0","endTime":"0","summary":"$和黄医药(00013)$周四午后股价大幅走高，一度升逾16%，势创2022年11月以来最大单日升幅。消息面上，和黄医药周四宣布，旗下公司与$葛兰素史克(GSK)$附属公司签署独家开发及许可协议，双方将合作开发及商业化在研肿瘤药物HMPL-A830。根据协议，和黄医药将获得1.1亿美元首付款，并有权获得最高12.95亿美元的开发、监管及商业化里程碑付款，以及产品上市后的净销售额特许权使用费。受大额授权合作消息刺激，和黄医药午后获资金明显追捧，股价升幅迅速扩大。","market":"us","thumbnail":"https://static.tigerbbs.com/25bb080e73b6be662c435ea6aeaec9c7","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/25bb080e73b6be662c435ea6aeaec9c7"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSKH","GSK","00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663282078","title":"藥聞 | 英硅智能上市後首份半年報扭虧 創新藥研發加速擁抱AI","url":"https://stock-news.laohu8.com/highlight/detail?id=2663282078","media":"新华财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663282078?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 15:35","pubTimestamp":1788161758,"startTime":"0","endTime":"0","summary":"新华财经上海8月31日电（记者杜康）作为AI制药领域代表性企业之一，英硅智能（03696.HK）日前发布2026年度中期业绩报告。上半年，公司实现总营收1.063亿美元，同比增长287.2%；净利润3554万美元，经调整净利润5123万美元，经营活动现金流转正。这是英硅智能上市后发布的首份半年报，公司也由此前的亏损转为盈利。从收入结构看，药物研发与管线开发仍是主要来源。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608313860072952.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608313860072952.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["CHAT","QTOC","BIOY","AGIX","GDOC","IPOS","LFSC","WRND","GSKH","APXH","BBP","BK4585","SBIO","IBB","XLVI","ARTY","AIPO","PBE","VTHR","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663044177","title":"聯環藥業上半年扭虧為盈 集採續採與創新藥研發協同推進","url":"https://stock-news.laohu8.com/highlight/detail?id=2663044177","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663044177?lang=zh_tw&edition=fundamental","pubTime":"2026-08-30 21:12","pubTimestamp":1788095520,"startTime":"0","endTime":"0","summary":"业绩实现扭亏为盈经营基本面持续改善今年上半年，联环药业经营业绩实现明显改善。对此，联环药业正持续推进相关工作。值得注意的是，联环药业已经开始围绕创新药商业化进行营销体系布局。除LH-1801外，联环药业产品注册申报也取得阶段性进展。从核心产品稳定销售，到集采品种持续放量，再到创新药研发向上市申报环节推进，联环药业正在逐步形成多层次的业务增长支撑。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-30/doc-iniqcfmp8061523.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-30/doc-iniqcfmp8061523.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["WRND","GSKH","PBE","BK4588","LFSC","BBP","SBIO","BIOY","APXH","XLVI","BK4585","GDOC","IBB","BK0239","600513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662606708","title":"能夠治癒乙肝的新藥來了？專家：距離攻克乙肝仍有差距，但臨床多了一件新武器","url":"https://stock-news.laohu8.com/highlight/detail?id=2662606708","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662606708?lang=zh_tw&edition=fundamental","pubTime":"2026-08-28 19:15","pubTimestamp":1787915749,"startTime":"0","endTime":"0","summary":"乙肝治疗领域迎来历史性突破。近日，葛兰素史克（GSK）宣布，其反义寡核苷酸（ASO）药物贝普若韦生（Bepirovirsen）已在日本获批上市，用于治疗既往接受过至少6个月核苷（酸）类似物治疗且符合预先设定的病毒学指标的成年慢性乙型肝炎（CHB）病毒感染患者，以达到功能性治愈的目的。据悉，这是Bepirovirsen在全球范围内的首次获批。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608283858475454.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608283858475454.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["ASO","BK4200","BK4017","LU1223083913.SGD","LU1223082196.USD","BK4007","GSK","BK4532","GSK.UK","GDXJ","BK4588","IBBQ","CDE","LU1223082519.USD","CHB","BK4561","XME","SGDM","LU1829250122.USD","GSKH","CAM","SIL","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662081157","title":"葛蘭素史克(GSK)擬發行至少20億歐元債券，以償還併購融資貸款。","url":"https://stock-news.laohu8.com/highlight/detail?id=2662081157","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662081157?lang=zh_tw&edition=fundamental","pubTime":"2026-08-27 18:00","pubTimestamp":1787824828,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["GSK.UK","BK4532","LQPE","MNA","GSK","BK4588","BK4585","TFNS","LBO","FXE","PEX","MRGR","FYLG","NBIE","GSKH","RSPF","BUYO","ARB","BK4007","BNDW","LU1829250122.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662752987","title":"博濟醫藥2026年半年報：創新藥研發需求復甦，在手訂單充足，經營現金流明顯下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2662752987","media":"蓝鲸财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662752987?lang=zh_tw&edition=fundamental","pubTime":"2026-08-27 14:57","pubTimestamp":1787813849,"startTime":"0","endTime":"0","summary":"然而，需警惕新药研发政策变化、项目执行延期及市场竞争加剧带来的风险，同时关注经营现金流与净利润背离的情况。后续需重点关注公司在手订单转化进度、临床前及临床研究服务的毛利率变化趋势，以及经营现金流的改善情况。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1787797151251328663","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BBP","GDOC","XLVI","BK4585","BK0216","SBIO","159399","IBB","BK4588","GSKH","SPHQ","APXH","WRND","300404","LFSC","PBE","BIOY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660493380","title":"GSK：NUCALA獲加拿大藥品管理局積極報銷推薦，用於成人慢性阻塞性肺疾病治療。","url":"https://stock-news.laohu8.com/highlight/detail?id=2660493380","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660493380?lang=zh_tw&edition=fundamental","pubTime":"2026-08-18 22:23","pubTimestamp":1787062997,"startTime":"0","endTime":"0","summary":null,"market":"uk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["GSK.UK","BK4007","BK4585","GSKH","BK4588","GSK","LU1829250122.USD","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660456776","title":"中外製藥與葛蘭素史克簽署抗登革熱病毒抗體「AID351」獨家許可協議","url":"https://stock-news.laohu8.com/highlight/detail?id=2660456776","media":"第一财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660456776?lang=zh_tw&edition=fundamental","pubTime":"2026-08-18 10:49","pubTimestamp":1787021377,"startTime":"0","endTime":"0","summary":"【中外制药与葛兰素史克签署抗登革热病毒抗体“AID351”独家许可协议】据中外制药官网消息，8月18日，中外制药宣布已与葛兰素史克签署独家许可协议，葛兰素史克将获得抗登革热病毒抗体药物“AID351”的全球独家开发、生产和商业化权利，并负责该药物的临床开发及生产。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608183844335660.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608183844335660.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["GSKH","BK4585","BK1191","BK4532","BK1574","LU1829250122.USD","GSK.UK","01477","BK4588","BK4007","GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660456160","title":"中外製藥與葛蘭素史克達成協議，共同推進登革熱抗體藥物開發","url":"https://stock-news.laohu8.com/highlight/detail?id=2660456160","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660456160?lang=zh_tw&edition=fundamental","pubTime":"2026-08-18 10:38","pubTimestamp":1787020681,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4585","GSK.UK","BK4588","BK4007","LU1829250122.USD","GSKH","BK4532","GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659504119","title":"中國銀河證券：實驗動物為創新藥研發剛需 小鼠+猴雙主線高景氣","url":"https://stock-news.laohu8.com/highlight/detail?id=2659504119","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659504119?lang=zh_tw&edition=fundamental","pubTime":"2026-08-14 15:07","pubTimestamp":1786691225,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中国银河证券发布研报称，实验动物为创新药研发刚需，行业壁垒深厚，两大细分赛道具备中长期成长逻辑：人源化小鼠赛道成长确定性更强、周期波动平缓;实验猴赛道供给约束强，短期价格上行带来显著业绩弹性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479960.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["601881","BK0276","BK1147","06881","BIOY","GDOC","LFSC","WRND","GSKH","BK0188","APXH","BBP","BK4585","SBIO","IBB","XLVI","BK1564","161027","PBE","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659945158","title":"葛蘭素史克：董事會批准根據公司淨資產，按資產市場價值分配公司合併後股本。","url":"https://stock-news.laohu8.com/highlight/detail?id=2659945158","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659945158?lang=zh_tw&edition=fundamental","pubTime":"2026-08-13 17:58","pubTimestamp":1786615104,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["GSK","GSKH","BK4007","BK4532","BK4585","GSK.UK","LU1829250122.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658903675","title":"百花醫藥股價嚴重異常波動：主營小分子化學仿製藥CRO業務 不涉及創新藥研發","url":"https://stock-news.laohu8.com/highlight/detail?id=2658903675","media":"央广财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658903675?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 21:27","pubTimestamp":1786541220,"startTime":"0","endTime":"0","summary":"8月12日，百花医药（维权）（600721.SH）发布公告称，公司股票连续10个交易日内日收盘价格涨幅偏离值累计超过100%，根据上交所的有关规定，属于股票交易严重异常波动情形。公司是以小分子化学仿制药研发为主的CRO企业，不涉及创新药研发。公司2026年第一季度实现营业收入6718.29万元，同比下降30.68%，归属于上市公司股东的净利润664.27万元，同比下降67.94%。目前公司主营业务未发生重大变化，市场环境、行业政策没有发生重大调整，股价短期内连续上涨，涨幅与公司经营情况严重偏离。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-12/doc-ininamih5206238.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BBP","PBE","GSKH","LFSC","BK0102","GDOC","600721","BK4585","BK4588","BK0216","SBIO","WRND","APXH","IBB","BIOY","XLVI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658692990","title":"百花醫藥(600721.SH)：不涉及創新藥研發","url":"https://stock-news.laohu8.com/highlight/detail?id=2658692990","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658692990?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 20:03","pubTimestamp":1786449780,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LFSC","WRND","BBP","APXH","BK4588","BIOY","GDOC","GSKH","SBIO","PBE","IBB","XLVI","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658667990","title":"百花醫藥(600721.SH)：不涉及創新藥研發","url":"https://stock-news.laohu8.com/highlight/detail?id=2658667990","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658667990?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 20:03","pubTimestamp":1786449780,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百花医药(600721.SH)发布股票交易风险提示公告称，公司是以小分子化学仿制药研发为主的CRO企业，主营业务是为客户提供小分子化仿药为主的药物研发注册“一站式”全流程服务，主要研发项目多来自于客户委托加部分的公司自主立项，不涉及创新药研发。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478640.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["WRND","SBIO","LFSC","PBE","APXH","BK0102","BK0216","GDOC","BIOY","BK4585","BBP","GSKH","XLVI","IBB","BK4588","600721"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658962968","title":"東方證券：AI重構創新藥研發底座 國內相關產業鏈公司亦有望受益","url":"https://stock-news.laohu8.com/highlight/detail?id=2658962968","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658962968?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 14:06","pubTimestamp":1786428403,"startTime":"0","endTime":"0","summary":"东方证券主要观点如下：技术颠覆成本，AI重构制药“快与省”是中国创新药崛起的底层逻辑，根基是人才红利和成本优势。专家与AI协同，将真正提升新药研发的成功率并缩短周期。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478422.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["GDOC","BK4588","AIPO","LFSC","BK1147","IBB","BIOY","BK4585","SBIO","BK0012","BK0028","BK1564","BK0188","BK0183","CHAT","PBE","WRND","ARTY","APXH","600958","QTOC","03958","BBP","BK0276","XLVI","VTHR","GSKH","AGIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658931998","title":"數據簡報-全球製藥企業斥資數十億以擴大在美國的市場份額","url":"https://stock-news.laohu8.com/highlight/detail?id=2658931998","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658931998?lang=zh_tw&edition=fundamental","pubTime":"2026-08-10 21:18","pubTimestamp":1786367928,"startTime":"0","endTime":"0","summary":"数据简报-全球制药企业斥资数十亿以扩大在美国的市场份额修改发稿日期，补充百时美施贵宝的投资计划路透8月10日-全球制药企业正扩大在美国的业务布局，承诺投入数十亿美元以提升该国的生产能力和研发实力。该公司于6月表示，已在佛罗里达州杰克逊维尔投资约10亿美元，以加强其眼科护理业务在美国的制造能力。赛诺菲计划通过直接投资公司现有基地以及与其他国内制造商建立合作伙伴关系，扩大其在美国的生产能力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL4T4470YN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU0057025933.USD","BK7501","LU0094547139.USD","IE00BKPKM429.USD","LU1066053197.SGD","ABBV","LU1069344957.HKD","LU0320765489.SGD","LU2471134952.CNY","LU2023250330.USD","LU2063271972.USD","LU0130102774.USD","LU0072461881.USD","LU0426417589.USD","LU0943347566.SGD","IE0034235303.USD","PBE","LU0109394709.USD","PFE","IE0002141913.USD","LU2089284900.SGD","LU0265550946.USD","PJP","SG9999015358.SGD","LU1057294990.SGD","LU1061106388.HKD","LU0320765646.SGD","SG9999014914.USD","LU2129689431.USD","SG9999002224.SGD","SGXZ80539844.SGD","LU2271345857.HKD","LU2347655156.SGD","BK4550","LU0795875169.SGD","LU2461242641.AUD","CURE","LU1037948541.HKD","LU0345769631.USD","BK4504","IE00BVYPNW00.USD","LU0109391861.USD","BIIB","LU1868836591.USD","LU1989771016.USD","BK4592","BK4585","LU0070217475.USD","IE0004445015.USD","LU0133085943.USD","LU0985320562.USD","IE00BVYPNV92.GBP","LU0266013472.USD","LU2133065610.SGD","SGXZ81514606.USD","BK4139","LU2237443382.USD","LU0553294199.USD","SG9999018865.SGD","GSK","IE00BLSP4239.USD","LU2213496289.HKD","LU2361044949.HKD","LU1093756325.SGD","LU1935042991.SGD","BIB","LU2430703095.HKD","SG9999015978.USD","LU1066051225.USD","LU0965508806.USD","LU0097036916.USD","LU2746668974.SGD","IE00BJJMRZ35.SGD","LU1814569148.SGD","LU0354030511.USD","LU0545562505.USD","LU2491050071.SGD","SG9999015945.SGD","LU1868837136.USD","LU0861579265.USD","LU1291159041.SGD","BK4599","IBBQ","LU2168564222.USD","IE0000B7K699.USD","LU1116320737.USD","LU2471134879.HKD","IE0002270589.USD","LU1670711123.USD","LU2552382132.HKD","GLAM","LU2471134523.USD","IE00B775H168.HKD","LU2168563687.JPY","SG9999014898.SGD","IE00B3PB1722.GBP","IE00BKVL7J92.USD","SG9999015952.SGD","JNJ","XLV","LU0029864427.USD","LU2468319806.SGD","IE00BBT3K403.USD","LU0256863902.USD","LU0211328371.USD","IE00BN8TJ469.HKD","BK4568","LU1712237335.SGD","LU2089283258.USD","IE000M9KFDE8.USD","LU2746668461.USD","LU2125909247.SGD","LU1506573853.SGD","LU0708995401.HKD","LU1261432733.SGD","AGNG","BK4566","LU1548497426.USD","LU2403377893.USD","AZN","SG9999014542.SGD","LU2125154778.USD","TMED","PAWZ","LU1196500208.SGD","LU0417517546.SGD","LU1221951129.SGD","SGXZ51526630.SGD","WDNA","LU0208291251.USD","LU1988902786.USD","LU1718418525.SGD","LU0820562030.AUD","LU0210536198.USD","LU1868836757.USD","LU0820561818.USD","LU2505996509.AUD","LU1551013342.USD","IE00BFSS8Q28.SGD","IE0001KFT4U8.USD","LU1032955483.USD","LU1145028129.USD","LU2750360641.GBP","SG9999014880.SGD","LU0882574139.USD","LU2456880835.USD","LU2129689514.USD","BK4581","SG9999011175.SGD","LU1127390331.HKD","IE00BGHQF631.EUR","LU0823416689.USD","LU0203201768.USD","ELIS","LU0070302665.USD","AZNH","IE00BDGV0183.EUR","IE00BJT1NW94.SGD","LU0545039389.USD","LU1043141396.HKD","IE00BN29S564.USD","LU0471298777.SGD","LU0395794307.EUR","LU1069347547.HKD","FHLC","LU0306807586.USD","LU2471134796.USD","LU1804176565.USD","LLY","MEDI","RXL","LU0661504455.SGD","LU1059921491.USD","LU0889565916.HKD","HRTS","SG9999002232.USD","IE00BJJMRX11.SGD","LU1883839398.USD","LU2462157665.USD","LU1670711040.USD","LU1914381329.SGD","IE00B19Z3B42.SGD","LU0689472784.USD","LU2552382215.SGD","LU2487616109.SGD","LU1037948897.HKD","LU0203202063.USD","LU2357305700.SGD","LU1941712264.USD","BK4533","LU2505996681.GBP","IE0004445239.USD","IE00BFTCPJ56.SGD","LU0225284248.USD","LU0320765992.SGD","IE00B19Z9Z06.USD","LU0385154629.USD","LU0868494617.USD","LU1267930813.SGD","IXJ","LU0949170772.SGD","LU2491049909.HKD","LU0211331839.USD","LU0289961442.SGD","LU2360106947.USD","LU2592432038.USD","SG9999018857.SGD","LU0942090050.USD","LU1571399168.USD","SG9999014567.USD","LU0640476718.USD","LU1732799900.SGD","AMGN","SG9999001176.USD","LU1093756168.USD","LU1670710661.SGD","LU1003077747.HKD","LU1043141123.HKD","LU1894683348.USD","NVOX","GB00BDT5M118.USD","IE00B3T34201.USD","LU1674673691.USD","CANC","LU2111349929.HKD","SG9999003800.SGD","LLYX","LU0511384066.AUD","BMY","LU1983299246.USD","LU1670628061.USD","IYH","LU2237443549.SGD","LU0306806265.USD","LU2462591350.SGD","LU2596442595.SGD","IE000F7OJYX1.SGD","IE000MB6IJN5.SGD","IE00BFSS7M15.SGD","LU1244550577.SGD","LU2168564065.EUR","BK4578","LU1228905540.USD","LU0265550359.USD","TBXU","LU1267930573.SGD","LU0320765059.SGD","LU0471298694.HKD","LU1244550221.USD","LU1974910355.USD","LU1674673428.USD","BK7067","LU0477156953.USD","IE000SO60NU8.SGD","LU0708994859.HKD","LU1670627923.USD","LU0823434740.USD","LU2125909593.SGD","LU2087621335.USD","LU0689626769.HKD","SG9999014906.USD","IE00B42XCP33.USD","LU2242646821.SGD","LU2347655073.USD","LU1064131342.USD","LU1162221912.USD","LU1267930730.SGD","LU0198837287.USD","IBB","LU0738911758.USD","LU1829250122.USD","LU0170899867.USD","LU0323591593.USD","LU0980610538.SGD","LU2087625088.SGD","LU0124676726.USD","LU0965509283.SGD","IE00B1XK9C88.USD","LU0345769128.USD","LU2756315318.SGD","BBH","LU1430594728.SGD","LU1232071149.USD","BK4534","LU1720051108.HKD","LU0353189763.USD","LU2023251221.USD","LU0211327993.USD","LU0321505439.SGD","LU1917777945.USD","LU0432979614.USD","BK4588","IE00B4JS1V06.HKD","LU1244550494.USD","IE0009355771.USD","IHE","LU1868836914.USD","LU1066051498.USD","LU2265009873.SGD","LU0006306889.USD","LU1778281490.HKD","IE00B1BXHZ80.USD","LU1201861249.SGD","LU0098860793.USD","LU0069063385.USD","LU0683600562.USD","LU2430703251.USD","LU2028103732.USD","LU0158827948.USD","LU0792757196.USD","LU0820561909.HKD","LU2360032135.SGD","LU0130517989.USD","LU0061475181.USD","LU0237698245.USD","LU0345770993.USD","LU0912757837.SGD","IE00BJJMRY28.SGD","LU2324357040.USD","BK7511","LU1670710588.SGD","LU0726765562.USD","LU1934455863.HKD","THNR","LU0787776722.HKD","CSL.AU","LU2361045086.USD","LU0466842654.USD","LU0162691827.USD","BK4583","LU2168564149.EUR","LU0672654240.SGD","LU0353189680.USD","LU2491050154.USD","LU0316494557.USD","SGXZ57979304.SGD","LU0786609619.USD","IE00BFXG1179.USD","LU0994945656.USD","LU2264538146.SGD","LU1066051811.HKD","LU1989772840.SGD","LU1032466523.USD","LU2430703178.SGD","SG9999001440.SGD","SG9999015341.SGD","LU2108987350.USD","LU2237443978.SGD","BK7508","LU1934455277.USD","IE00BK4W5L77.USD","LU2089984988.USD","SG9999001176.SGD","SG9999015986.USD","IE00BZ1G4Q59.USD","LU0795875086.SGD","LU2112291526.USD","LU1366192091.USD","LU1035775433.USD","IE00B7KXQ091.USD","LU0345770308.USD","LU0310800379.SGD","LU0456855351.SGD","IE00B19Z3581.USD","LU1585245621.USD","LU1894683264.USD","SG9999013999.USD","IE00B4R5TH58.HKD","FTXH","LU1720051017.SGD","LU1934455194.USD","GDOC","IE00BJLML261.HKD","LU2552382058.USD","LU2417539215.USD","LU2602419157.SGD","LU1929549753.HKD","LU2242652126.USD","LU1116320901.HKD","LU1989772923.USD","LU0210528500.USD","LU0859254822.USD","LU1699723380.USD","LU0310799852.SGD","GILD","LU0472753341.HKD","LU0965509101.SGD","SG9999014575.USD","LU1623119135.USD","LU0096364046.USD","SGXZ99366536.SGD","LU0868494708.USD","IE000WAW04H5.SGD","LU0079474960.USD","BMED","LU1228905037.USD","ELIL","LU1280957306.USD","LU0648001328.SGD","LU1221951046.USD","LU0965509010.AUD","LU2023250843.SGD","LU0267386448.USD","LU0354030438.USD","SG9999014559.SGD","LU2237443895.HKD","IE00BWXC8680.SGD","LU0203345920.USD","LU0225283273.USD","LU0321505868.SGD","LLYZ","LU1551013425.SGD","LU2106854487.HKD","LU1979441026.SGD","LLII","LU2357627491.SGD","IE00BLSP4452.SGD","LU0882574055.USD","LU2236285917.USD","LU2433249047.HKD","LU0426412945.USD","IE000BZT7R73.USD","LU0174119429.USD","IE00B2B36J28.USD","PPH","BK4532","LU2125154935.USD","GSKH","GSK.UK","LU0154236417.USD","LU0238689110.USD","ILDR","LU2168564495.EUR","LU0106261372.USD","LU0256863811.USD","LU2237438978.USD","BK4559","LU1629891620.HKD","IE00BK4W5M84.HKD","LU1941712348.USD","LU2237443465.HKD","LU1121112475.USD","LU1496350171.SGD","LU1496350502.SGD","LU0289739343.SGD","NVOH","IE00B894F039.SGD","LU0128525929.USD","LU1267930490.SGD","LU1023059063.AUD","LU1074936037.SGD","IE00BSNM7G36.USD","BK4516","LU0225771236.USD","SGXZ31699556.SGD","04332","LU0122379950.USD","NVO","OZEM","LU2756315664.SGD","MHIP","LU2129689605.HKD","LU0964807845.USD","LU0234572021.USD","VHT","IE00B19Z9P08.USD","LU0114720955.EUR","SG9999017495.SGD","LU0289739699.SGD","TRUH","LU0823434583.USD","IE00BKDWB100.SGD","LU0058720904.USD","LU1839511570.USD","LU2896262040.SGD","MEDX","MRK","IE00B7SZLL34.SGD","LU2211815571.USD","LU0889566641.SGD","LU1923622614.USD","LU2361044865.SGD","LU1035773651.USD","LU0158827781.USD","LU0053666078.USD","IE0005OL40V9.USD","LU1323610961.USD","LU1732800096.USD","LU1868837300.USD","LU2237443622.USD","LU0203347892.USD","LU2023250504.SGD","LU0234570918.USD","LU0985481810.HKD","LU2750360997.AUD","JDOC"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":96,"code":"91000000","status":"200"}]}}